The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer

Abstract Objective Although the current European Association of Urology(EAU) guideline recommends that patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) should accept intravesical chemotherapy or Calmette-Guerin (BCG) for no more than one year after transurethral resection o...

Full description

Bibliographic Details
Main Authors: Jian-Xin Chen, Wen-Ting Huang, Qing-Yun Zhang, Cheng-En Deng, Jue-ling Wei, Yuan-Liang Xie, Rui Lin, Guan-Zheng Feng, Guang-Lin Yang, Jun Long, Hao-Yuan Lu, Zeng-nan Mo
Format: Article
Language:English
Published: BMC 2023-10-01
Series:BMC Cancer
Subjects:
Non-muscle-invasive Bladder cancer
Intravesical chemotherapy
Pirrubicin
Tumor recurrence
Online Access:https://doi.org/10.1186/s12885-023-11523-9

Internet

https://doi.org/10.1186/s12885-023-11523-9

Similar Items